GT BIOPHARMA, INC. Increase (Decrease) in Accounts Receivable
GT BIOPHARMA, INC. (GTBP) reported Increase (Decrease) in Accounts Receivable of $0 for the 9-month period ending 2016-09-30, per its 10-Q/A filed 2018-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2018-02-28
- GT BIOPHARMA, INC. increase (decrease) in accounts receivable for the quarter ending 2016-09-30 was $0.00.
- GT BIOPHARMA, INC. increase (decrease) in accounts receivable for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. increase (decrease) in accounts receivable for the quarter ending 2015-06-30 was $0.00.
- GT BIOPHARMA, INC. increase (decrease) in accounts receivable for the quarter ending 2015-03-31 was $0.00.
- GT BIOPHARMA, INC. increase (decrease) in accounts receivable for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- GT BIOPHARMA, INC. increase (decrease) in accounts receivable for fiscal 2013 was $40.00K.
- GT BIOPHARMA, INC. increase (decrease) in accounts receivable for fiscal 2012 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2016-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-02-28 | $0.00 10-Q/A · filed 2018-02-28 | |||||
| 2016-06-30 | $0.00 10-Q/A · filed 2018-02-28 | ||||||
| 2015-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-02-28 | $0.00 derived: sum of 2 quarters · filed 2018-02-28 | $0.00 10-Q/A · filed 2018-02-28 | $0.00 derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2015-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q 3 month · filed 2018-02-28 | $0.00 10-Q/A · filed 2018-02-28 | $0.00 derived: sum of 3 quarters · filed 2018-02-28 | $35.00K derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-14 | $0.00 derived: sum of 2 quarters · filed 2015-05-14 | $35.00K derived: sum of 3 quarters · filed 2015-11-13 | $10.00K derived: sum of 4 quarters · filed 2015-11-13 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $35.00K derived: sum of 2 quarters · filed 2015-11-13 | $10.00K derived: sum of 3 quarters · filed 2015-11-13 | $0.00 10-K · filed 2015-03-31 | |||
| 2014-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $10.00K derived: sum of 2 quarters · filed 2015-11-13 | $0.00 10-Q · filed 2015-11-13 | ||||
| 2014-06-30 | -$25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | -$35.00K 10-Q · filed 2015-08-14 | $35.00K 10-Q · filed 2015-01-08 | ||||
| 2014-03-31 | -$10.00K 10-Q · filed 2015-05-14 | $10.00K 10-Q · filed 2015-01-08 | |||||
| 2013-12-31 | $40.00K 10-K · filed 2015-03-31 | -$40.00K 10-K · filed 2015-01-08 | |||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-01-08 | $0.00 10-Q · filed 2015-01-08 | |||||
| 2013-03-31 | $0.00 10-Q · filed 2015-01-08 | ||||||
| 2012-12-31 | $0.00 10-K · filed 2015-01-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |